April 11, 2025 | Shanghai-SIMR Biotech today announced that it will present topline results from a Phase Ib study of SR1375, a first-in-class oral lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, in hospitalized pneumonia patients with comorbidities, at the 2025 American Thoracic Society (ATS) International Conference, to be held May 16-21 in San Diego, California.
The presentation will highlight that Lp-PLA2 is a biomarker for pneumonia severity, with higher Lp-PLA2 activity linked to increased mortality in hospitalized pneumonia patients, while SR1375 has the capacity to reduce patient mortality.
“We are thrilled to share our latest Phase Ib data demonstrating SR1375's significant potential to reduce mortality risk in hospitalized patients with moderate to severe pneumonia.” said Dr. Li Shuai, CEO of SIMR Biotech. “These findings position SR1375 as a much-needed novel therapy for hospitalized pneumonia patients, especially against the backdrop of worsening population aging, noxious side effects of existing anti-inflammatory drugs, and increasing antibiotic resistance.”
SR1375 Poster Presentation at ATS 2025:
Title: “SR1375, a Novel Lipoprotein-Associated Phospholipase A2 Inhibitor as an Effective Oral Drug Candidate for Pneumonia With Comorbidities: Results From a Phase Ib Study”
Session Type: Poster Presentation
Date/Time: May 20, 2025 | Session: C66-LATE BREAKING SCIENCE IN PULMONARY INFECTIONS
About SR1375:
SR1375 targets Lp-PLA2, a key enzyme driving cytokine storm, endothelial damage, and epithelial dysfunction during acute inflammation. The molecule has shown a placebo-comparable safety profile in over 100 healthy volunteers and patients enrolled to date. SR1375 is currently in Phase II clinical trials for pneumonia with comorbidities, further evaluating its therapeutic potential.
Clinical trial web link: https://clinicaltrials.gov/study/NCT06577558
ID: NCT06577558
